Help
3577 Article Views
Publication Date: 30 Apr 2009
Journal: Clinical Medicine Insights: Therapeutics
P. Tatti
Endocrinology and Diabetes Unit, ASL RMH Rome.
Abstract
Rosiglitazone is a member of the Thiazolidinedione class of drugs with a potent insulin sensitizing action. The drug has been extensively used and many early warnings on its potential risks were ignored mostly due to an aggressive commercial strategy. In 2007 some papers raised doubts on the cardiovascular safety of the drug and started a serious dispute. Irrespective of the real existence of this risk the story of Rosiglitazone led to the unveiling of many other side effects and emphasizes the need for a more accurate evaluation of any drug before is approved by the regulatory authority.
The submission process for manuscript publication in Breast Cancer: Basic and Clinical Research is as easy as A,B,C! Any minor hiccups I encountered were quickly addressed by Libertas' expert staff via prompt emails, and the timelines between initial submission and publication are surely the shortest on record! I will definitely be submitting future manuscripts to this journal, and look forward to working with their professional and expert team.Dr Maggie Laidlaw (Nutrasource Diagnostics Inc, Guelph, Ontario, Canada) What Your Colleagues Say
Copyright © 2012 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
FacebookGoogle+Twitter
PinterestTumblrYouTube